Bora Pharmaceuticals (6472.TW)

Executive Summary

Bora Pharmaceuticals is a leading Taiwanese contract development and manufacturing organization (CDMO) and pharmaceutical company, publicly traded on the Taiwan Stock Exchange (6472.TW). The company specializes in the development, manufacturing, and commercialization of a diverse portfolio of generic and branded pharmaceutical products, with a strong focus on the Asian and global markets. With a market capitalization of approximately $1.57 billion, Bora has established itself as a key player in the CDMO space, leveraging its expertise in oral solid dosage forms and sterile injectables. The company's growth strategy includes capacity expansion, strategic partnerships, and entry into high-value segments such as biosimilars and complex generics. Recent investments in new manufacturing facilities and R&D capabilities position Bora to capture increasing demand from both domestic and international clients, particularly in the US and European markets. However, the company faces competitive pressures from larger global CDMOs and regulatory risks associated with manufacturing compliance.

Upcoming Catalysts (preview)

• Q4 2025Completion of new manufacturing facility in Taiwan or Southeast Asia80% success
• Q3 2025Major contract win from a top US or European pharmaceutical company40% success
• Q1 2026FDA approval for a complex generic drug filed by Bora or its client50% success